2 Stocks That Could Realistically Double by 2030

The article highlights two speculative biotech names, Abivax and Viking Therapeutics, with major clinical catalysts expected over the next 12-18 months and into 2027. Abivax is awaiting phase 3 maintenance data for obefazimod in ulcerative colitis before quarter-end, while Viking expects phase 3 readouts for VK2735 within 12-18 months and plans to start oral VK2735 phase 3 by year-end. Both stocks are framed as high-risk but potentially high-upside if trial results and regulatory progress are favorable.

Analysis

The market is increasingly valuing these names as binary catalyst vehicles rather than platforms, which creates asymmetric upside if data is clean but very limited tolerance for any ambiguity. In both cases, the first derivative matters less than the follow-through: for ABVX, the maintenance readout is about proving durability and payer-worthy consistency, while for VKTX the phase 3 package must de-risk both efficacy and tolerability versus a crowded GLP-1 landscape. That means the biggest moves are likely to come on clean data and/or partnering discussions, not on gradual fundamental improvement.

Second-order, the real winner may be differentiated formulation and convenience, not just molecule strength. For VKTX, an oral option and a distinct mechanism can matter more than headline weight-loss efficacy because it broadens the addressable patient pool and gives it a shot at patients who are already GLP-1 fatigued or side-effect sensitive. For ABVX, the opportunity is narrower but potentially more defensible if the drug avoids broad immunosuppression; that could translate into better persistence and less switching, which is what ultimately drives durable revenue in IBD.

The contrarian read is that both names may already embed a lot of “good news optionality.” ABVX’s valuation implies approval plus meaningful commercial uptake, so even a technically positive dataset may disappoint if the market expected near-flawless execution. VKTX faces a similar issue: success in obesity is necessary but not sufficient, because investors will quickly ask how it differentiates against incumbents with deeper distribution and pricing power. The key risk window is the next 3-18 months, when catalyst-driven upside is real but any trial miss, CMC issue, or safety signal could erase a large share of market cap.

Positioning should favor event-driven structures over outright long equity if volatility is already elevated. The better trade is to own optionality into the data while capping downside, because the base case is not steady compounding but large gap moves around discrete readouts.

Key Decisions for Investors

• VKTX: Buy medium-dated calls or call spreads into the phase 3 window over the next 3-6 months; structure for a 2-3x payout if data is clean, but cap premium at risk in case of a miss.
• ABVX: Avoid chasing common stock ahead of maintenance data; prefer a small starter long only after confirmation of durability, or use call spreads to express upside while limiting downside from an already rich valuation.
• Pair trade: Long VKTX / short a basket of late-stage obesity incumbents on any pre-data strength; the market may reward differentiated delivery if efficacy is comparable, but penalize undifferentiated assets in a crowded class.
• Event hedge: If long either name outright, hedge with short-dated puts or collars into the catalyst window; these are classic gap-risk equities where one negative endpoint can cut 30-50% overnight.
• Tactical timing: Add only on post-catalyst weakness if data is good but the stock sells off on crowded positioning; that is often the best entry point for the 6-12 month re-rating trade.